Copper(II)-induced Conformational Changes and Protease Resistance
in Recombinant and Cellular PrP
EFFECT OF PROTEIN AGE AND DEAMIDATION*
Kefeng
Qinab,
Dun-Sheng
Yanga,
Ying
Yangc,
M. Azhar
Chishtia,
Ling-Jie
Mengc,
Hans A.
Kretzschmard,
Christopher M.
Yipefg,
Paul E.
Fraserah, and
David
Westawayaij
From the a Centre for Research in Neurodegenerative
Diseases, the h Department of Medical Biophysics, the
i Department of Laboratory Medicine and Pathobiology,
c Mass Spectrometry Laboratory, Modern Medicine Research Centre,
the e Department of Chemical Engineering and Applied Chemistry,
f Institute of Biomaterials and Biomedical Engineering, and the
g Department of Biochemistry, University of Toronto,
Toronto, Ontario M5S 3H2, Canada, and the d Institüt
für Neuropathologie, Georg-August-Universität
Göttingen, 37075 Göttingen, Germany
Received for publication, September 13, 1999, and in revised form, March 27, 2000
 |
ABSTRACT |
While PrPC rearranges in the
area of codons 104-113 to form PrPSc during prion
infections, the events that initiate sporadic Creutzfeldt-Jakob disease
are undefined. As Cu(II) is a putative ligand for PrPC and
has been implicated in the pathogenesis of Creutzfeldt-Jakob disease
and other neurodegenerative diseases, we investigated the structural
effects of binding. Incubation of brain microsomes with Cu(II)
generated ~30-kDa proteinase K-resistant PrP. Cu(II) had little
effect on fresh recombinant PrP23-231, but aged protein characterized
by conversion of Asn-107 to Asp decreased
-helical content by
~30%, increased
-sheet content 100%, formed aggregates, and
acquired proteinase K resistance in the presence of Cu(II). These
transitions took place without need for acid pH, organic solvents,
denaturants, or reducing agents. Since conversion of Asn to Asp
proceeds by a spontaneous pathway involving deamidation, our data
suggest that covalent variants of PrPC arising in this
manner may, in concert with Cu(II), generate PrPSc-like
species capable of initiating sporadic prion disease.
 |
INTRODUCTION |
Prions are infectious pathogens that cause fatal neurodegenerative
diseases such as scrapie and Creutzfeldt-Jakob disease (CJD).1 Many lines of
evidence indicate that prions are comprised of an aberrant form of the
benign host-encoded neuronal glycoprotein, PrPC (1). The
infectivity-associated isoform of PrP known as PrPSc
differs from PrPC in several ways including higher
-sheet content and reduced
-helical content (2-5), partial
resistance to protease digestion (which yields an N-terminally
truncated form denoted PrP27-30 (6, 7)), and reduced detergent
solubility. Prion propagation is not thought to involve the replication
of a nucleic acid genome but is attributed to PrPSc
molecules templating the refolding of PrPC to create
further PrPSc molecules, emphasizing the distinction
between prions and viruses.
Although the notion of prion diseases as disorders of protein folding
is becoming increasingly accepted, many questions remain unanswered. If
PrPSc is the causative infectious agent, why are
10,000-100,000 molecules present per infectious unit? Does this number
imply the existence of sub-varieties of PrPSc? What is the
origin of sporadic CJD (sCJD), occurring at a rate of 0.5-1 case per
million? This transmissible disease is not attributable to iatrogenic
spread or germ line mutation in the human PrP gene (PRNP) and is
hypothesized to arise by very rare errors in PrPC
biochemistry that generate PrPSc-like molecules (8). The
nature of these events is obscure, however. Another question raised by
sCJD concerns the molecular basis of prion strains. These are distinct
isolates of agent with apparently true-breeding attributes that can be
propagated in the same inbred host. They are inferred to exist from
analyses of the variable neuropathology of sCJD (9, 10) and, more compellingly, from the passage properties of prions isolated from sheep
with natural scrapie (11). The existence of strains of scrapie prions
was widely interpreted to indicate the presence of a nucleic acid
genome (12); however, biochemical analyses have failed to provide
strong evidence for such an entity (13). More recent studies indicate
that strains are associated with PrPSc variants that can be
distinguished by protease cleavage sites in the vicinity of codon 90 (14, 15) or the accessibility of residues 104-113 to the 3F4 antibody
(16, 17). This fits well with the view from molecular genetics, since
the gene that controls susceptibility to prion strains, previously
referred to as Prn-i or Sinc, has been found to
correspond to a variant allele of the PrP gene (Prnp)
distinguished by missense changes at codons 108 and 189 (18-21).
Nonetheless, the exact molecular distinctions in this region remain to
be identified.
PrPC itself is expressed on the cell surface by virtue of a
glycosylphosphatidylinositol anchor. It is composed of an N-terminal domain, which includes reiterated octapeptide motifs of the general form P(H/G)GGGWGQ, and a pathogenesis-associated C-terminal domain that
can fold into proteinase-resistant, amyloidogenic aggregates (7, 22).
Although its function is debated, a growing body of evidence indicates
a role for Cu(II) (23). Binding of Cu(II) to the octapeptide motifs is
specific and cooperative (24-27), and cells from PrP gene-ablated
(Prnp%) mice have been reported as deficient in
membrane-associated Cu(II) (25, 28) and prone to toxic effects of
exogenous Cu(II) (29, 30). Possible physiological functions of
PrPC-Cu(II) complexes include transport, neuroprotection,
or redox enzymatic activity (25, 29, 31). As patterns of
protease-resistant PrP fragments characteristic for certain sCJD
subtypes can be interconverted via the prior use of metal chelators, it
is inferred that PrPSc is engaged with transition metals in
brain homogenates (32) and perhaps in vivo.
In this paper we examined structural consequences of metal binding to
PrP. The substrates comprised full-length recombinant mouse PrP
("rPrP," MoPrP23-231), which is highly soluble at neutral pH (33),
and PrPC isolated from brain homogenates. Our findings
reveal a divergence in the behavior of fresh and aged rPrP that is
correlated with conversion of Asn-107 to Asp, a modification first
described by Sandmeier et al. (34), although not previously
associated with alterations in structural properties. This covalent
change most likely occurs by a well known chemical pathway involving
deamidation and hydrolysis. Although studies of a rapid-onset prion
disease model found only 0.5 mol % D-aspartyl and
L-isoaspartyl residues in PrPSc, arguing
against an obligatory relationship between deamidation and
PrPSc formation (35), our biochemical studies suggest a
novel pathway for the formation of PrPSc-like molecules
perhaps germane to the origins of sporadic prion disease.
 |
EXPERIMENTAL PROCEDURES |
Recombinant Mouse PrP23-231--
Cells of Escherichia
coli BL2l(DE3) including pRBI-PDI-T7-MoPrP23-231 (pMoPrP23-231)
(33) were grown at 37 °C in 1 liter of LB containing ampicillin (100 µg/ml). At A600 nm = 0.8-1.0, isopropyl-1-thio-
-D-galactopyranoside was added to a
final concentration of 1 mM, and the culture was shaken at
37 °C for 16 h. The cells were harvested by centrifugation at
8000 rpm for 10 min, resuspended in 20 ml of suspension buffer (50 mM Tris-HCl, pH 8.0, 1 mM MgCl2, 0.4 mg/ml DNase I, 0.4 mg/ml RNase A, 1 mg/ml lysozme, 1 mM
phenylmethylsulfonyl fluoride), and shaken at 37 °C for 2 h and
at room temperature for 1 h. The cleared lysate was centrifuged at
4 °C at 39,000 × g for 1 h. The insoluble
inclusion bodies were washed twice with wash buffer (20 mM
Tris-HCl, pH 8.0, 23% sucrose (w/v), 0.5% Triton X-l00 (v/v), 1 mM EDTA, 1 mM benzamidine) and solubilized in
10 ml of 10 mM Tris-HCl, pH 8.0, 50 mM
dithiothreitol (DTT), 1 mM EDTA, 8 M urea.
After centrifugation at 39,000 × g at 22 °C for
1 h, the pH of the supernatant was adjusted to 7.0 with 0.1 mM HCl and applied to an SP-Sepharose column (20 ml,
Amersham Pharmacia Biotech) equilibrated with l0 mM
MOPS-NaOH, pH 7.0, 5 mM DTT, 1 mM EDTA, 8 M urea, using BioLogic HR chromatography system (Bio-Rad).
MoPrP23-231 was eluted with a linear NaCl gradient (0-0.6
M). Fractions containing MoPrP23-231 were pooled and
dialyzed against 10 mM MOPS-NaOH, pH 7.0, 5 mM
DTT, 1 mM EDTA, 8 M urea, then re-applied to an
SP-Sepharose column (20 ml). MoPrP23-231 was eluted with a linear NaCl
gradient (0-0.6 M). Pooled fractions containing
MoPrP23-231 were diluted with 50 mM Tris-HCl, pH 8.7, 8 M urea to a protein concentration of 0.05 mg/ml.
CuSO4 was added to a final concentration of 1 µM, and the solution was stirred for 2 h at room
temperature. Oxidation was quenched by addition of 1 mM
EDTA, and the pH of the solution was adjusted to 6.5 with 0.1 M HCl. The solution was dialyzed against water,
concentrated to 1 mg/ml, and stored at
20 °C. Alternatively,
recombinant mouse PrP23-231 (a gift from R. Glockshuber and co-workers)
was purified as described previously (33).
Amino Acid Analysis and Determination of Protein
Concentration--
Amino acid analysis was performed on a Waters
PICO-TAG System calibrated in triplicate using a collection of
derivatized amino acid standards. Dried MoPrP23-231 was hydrolyzed by a
vapor phase using 6 M HCl with 1% phenol at 110 °C for
24 h. After hydrolysis, excess HCl was removed from the hydrolysis
tube under vacuum, and the sample was derivatized, dissolved in sample
diluent pH (7.4), and an aliquot injected into a Water PICO-TAG column
running on a Waters PICO-TAG gradient with a column temperature of
33 °C. For tabulation of individual amino acids, yields are
expressed as percentage weight or percentage content with a molecular
weight correction for loss of one water molecule per residue.
Mass Spectrometric Molecular Weight Determination and Peptide
Mapping--
Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometric (MALDI-TOF-MS) analyses were carried
out using a Perspective Biosystem Voyager-DE STR mass spectrometer
(Perspective Biosystems Inc., Farmingham, MA) equipped with a pulsed UV
nitrogen laser (337 nm, 3-ns pulse) and a dual microchannel plate
detector. For molecular weight determination of full-length MoPrP23-231 protein, spectra were acquired at linear DE mode, acceleration voltage
set to 25 kV, grid voltage at 95% of the acceleration voltage, guide
wire voltage at 0.150%, delay time at 320 ns, and low mass gate set at
1000 Da; the mass to charge ratio was calibrated with the molecular
weight of a mixture of proteins (5734.58 to 16952.56 Da). For analysis
of tryptic peptides, the spectra were acquired at reflectron DE mode,
acceleration voltage set to 20 kV, grid voltage at 72% of the
acceleration voltage, guide wire voltage at 0.050%, delay time at 200 ns, low mass gate set at 250 Da, and the mass to charge ratio was
calibrated with the mass of
-cyano-4-hydroxycinnamic acid ([M + H]+ 379.09 Da) and the molecular weight of a mixture of
standard peptides (904.46 to 5734.58 Da). Saturated
-cyano-4-hydroxycinnamic acid in 70% acetonitrile containing 0.1%
trifluoroacetic acid was used as the matrix for analysis of tryptic
peptides, and saturated sinapinic acid in 50% acetonitrile containing
0.1% trifluoroacetic acid was used as the matrix for protein analysis.
One microliter of solution of MoPrP23-231 or tryptic peptide mixture
was applied on the MALDI plate followed by 1 µl of saturated matrix
solution. Spectra were recorded after evaporation of the solvent and
processed using GRAMS software for data collection and analysis.
S-Carbamidomethylation of Cysteines--
MoPrP23-231 (1 mg/ml)
in 50 µl of S-carbamidomethylation buffer including 0.1 M Tris-HCl, pH 8.0, 1 mM EDTA, 6 M
guanidine hydrochloride was incubated with or without 10 mM
DTT at room temperature for 1 h. The reduced or non-reduced
MoPrP23-231 was incubated with 50 mM iodoacetamide (IAM) at
room temperature in the dark for 30 min. Iodoacetamide reacts with free
SH group of cysteine to yield carbamidomethylcysteine. One microliter
of MoPrP23-231, reduced or non-reduced MoPrP23-231, treated with IAM
was used for MALDI-MS analysis without further purification. Predicted masses were calculated by the Peptide Mass program in ExPASy Home Page.
Measurement of Deamidation via Mass Spectroscopy--
Trypsin
digestion was carried out with 1 mg/ml MoPrP23-231 (fresh, stored in
water at
20 °C for 6 or 24 months) in 10 µl of 100 mM ammonium bicarbonate, pH 8.0, 1 mM
CaCl2. 0.5 µl of modified trypsin solution (Sequencing
grade, Promega, 2 mg/ml in 50 mM acetic acid) was added to
yield a final pH of 7.5 (enzyme:protein = 1:10). After incubation
at 37 °C for 2 h, an aliquot (1 µl) of the tryptic peptide
mixture was used for MALDI-MS analysis without further purification.
Atomic Force Microscopy--
Solution tapping mode atomic force
microscopy imaging was performed using a combination contact-tapping
mode liquid cell fitted to a Digital Instruments Nanoscope IIIA
MultiMode scanning probe microscope (Digital Instruments, Santa
Barbara, CA). All images were acquired using 120-µm silicon nitride
V-shaped cantilevers with integral oxide-sharpened pyramidal tips (type
DNP-S, Digital Instruments, Santa Barbara, CA). Prior to use, the AFM
tips were exposed to UV irradiation to remove adventitious organic
contaminants from the tip surface. The AFM images were acquired using
the E scanning head, which has a maximum lateral scan area of 14.6 × 14.6 µm. Optimal tapping mode imaging was achieved at a cantilever drive frequency of ~8.9 kHz with lateral scan rates between 1 and 2 Hz. Under these conditions, the free amplitude of the tip is <3 nm.
In situ AFM imaging of the mouse PrP protein was achieved by
transferring 5 µl of the MoPrP23-231 sample solution onto freshly cleaved mica previously affixed to an AFM sample puck. The sample was
immediately sealed in the AFM liquid cell, and the cell was filled with
the sample buffer solution. Image analyses were performed using the
Nanoscope software version 4.31 (Digital Instruments, Santa Barbara,
CA), and NIH Image.
Electron Microscopy--
MoPrP23-231 was incubated with 7-fold
excess (112 µM) CuCl2, NiSO4,
ZnCl2 (or without any divalent ion) at room temperature for
4 days. One-half of each sample was digested with PK (MoPrP:PK = 15:1) at 37 °C for 16 h. For negative staining electron
microscopy, 5 µl of each sample was applied to 300-mesh pioloform-
and carbon-coated copper grids, blotted dry, and stained with 0.1%
phosphotungstic acid, pH 7.0. Samples were then examined under a
Hitachi 7000 electron microscope with an accelerating voltage of 75 kV.
Circular Dichroism--
Far-UV CD measurements were performed by
a JASCO J-715 spectropolarimeter. By using a cell path length of 1 mm,
scans were conducted between 190 or 195 and 250 nm at a scan speed of
20 nm/min with a sensitivity of 50 millidegrees. All CD spectrum measurements were performed at room temperature in 25 mM
N-ethylmorpholine, 30 mM KCl (NEMO-KCl) buffer,
pH 7.4, as indicated in the figure legends. To assess the solubility of
the protein under these conditions, aliquots were removed subsequent to
each addition of Cu(II) and centrifuged in a Beckman TL100.3 rotor at
45,000 rpm (100,000 × g) for 30 min. Supernatants were
carefully removed, electrophoresed, and stained with Coomassie Blue.
Spectra were subject to curve-smoothing and converted into to [
]
mean residue ellipticities, in degree cm2/dmol, based on
the protein concentration determined by amino acid analysis using the
PICO-TAG system.
Peptide Sequencing--
MoPrP23-231 was incubated with 7-fold
molar excess of CuCl2 for 48 h, digested with PK as
above, electrophoresed on a 10-20% Tricine-SDS gel, transferred to a
polyvinylidene difluoride membrane, and stained by Coomassie Blue. The
membrane was sliced, and individual bands (see text) were sequenced
using a Porton Gas-phase Microsequencer model 2090 and on-line
phenylthiohydantoin analysis.
Preparation of Brain Microsome Fractions--
Subsequent to
sacrifice by carbon dioxide inhalation and in accord with the Canadian
Council for Animal Care guidelines, brains from
Tg(SHaPrP)7+/
heterozygous mice, genotyped by standard
methods (36), were removed and immediately frozen on dry ice. Mouse or
normal human brain samples were weighed, suspended in 0.32 M sucrose (10% w/v), and homogenized with 6-8 bursts of
10 s each using a Polytron homogenizer set at medium speed. Brain
homogenates were then processed to yield microsomes following the
method of Meyer et al. (37). To aid removal of extraneous
proteins, microsomal pellets were suspended in distilled water,
incubated for 30 min at room temperature, and then centrifuged at
100,000 × g for 1 h at 4 °C (37). The supernatant was discarded, and the pellet was resuspended again in
distilled water and stored at
20 °C for further experiments. 40 µl of microsome preparation (at a protein concentration of 0.8 mg/ml)
was incubated with or without 140 µM CuCl2,
ZnCl2, or NiSO4 at room temperature for 48 h. One-half of each sample was digested with proteinase K (50 µg/ml)
at 37 °C for 60 min. The samples were boiled in Tris glycine-SDS gel
loading buffer without
-mercaptoethanol and electrophoresed and
blotted as indicated.
 |
RESULTS |
Disulfide Bond Formation in MoPrP23-231--
In initial studies we
examined the properties of an N-terminal PrP23-98 fragment of
PrPC used previously for equilibrium dialysis binding
studies (25). This peptide yielded a random coil CD signature (as
anticipated (38-41)) that was little affected by addition of Cu(II).
However, Cu(II) exerted a profound influence on the intact GST/PrP23-98 fusion protein, decreasing the
-helical signature ~3-fold and increasing
-sheet content ~1.5-fold (as determined by standard algorithms (42, 43)). This effect was specific for Cu(II), was not due
to aggregation, and was absent from wild-type GST and GST/presenilin 1 fusion protein controls (data not presented). This unexpected finding
prompted a study of full-length PrP. For this purpose, recombinant
MoPrP23-231 expressed in E. coli was purified to
homogeneity, by minor modifications to a previously described protocol
(33). Of note, oxidation of purified MoPrP23-231 was performed for
2 h at room temperature at a protein concentration of 0.05 mg/ml
in 8 M urea at pH 8.7 with 1 µM
CuSO4 as a catalyst. After terminating the reaction by
addition of 1 mM EDTA, the sample was dialyzed against
water to remove urea and thereby promote refolding. MALDI-MS molecular
weight analysis of MoPrP23-231 showed a single charged protein signal
at m/z 23,108 ± 1.04 Da (Fig. 1, A1 and B1), in
excellent agreement with the calculated molecular mass of 23,107 Da as
[M + H]+. Mouse PrP contains two Cys residues at
positions 178 and 213 (44). To verify that the disulfide bond was
present in our recombinant MoPrP23-231, we used the
S-carbamidomethylation method. After incubation with or
without DTT at pH 8.0 in 6 M guanidine hydrochloride, MoPrP23-231 was incubated with iodoacetamide (IAM) and analyzed by
MALDI-TOF-MS. Fig. 1A1 shows that the mass of MoPrP23-231 is 23,109 Da (predicted mass of [M + H]+ is 23,107 Da).
Non-reduced MoPrP23-231 did not react with IAM in that its mass did not
change (22,099 Da, within the error limits 0.05% for this method of
analysis) (Fig. 1A2). After reduction with DTT,
carbamidomethylated MoPrP23-231 increased in mass by 110-23,209 Da
(the predicted gain in mass from two modifications is 114.0 Da and the
mass of the di-modified PrP species in the form [M + H]+
is 23,223 Da) (Fig. 1A3). These results indicate one
disulfide bridge per molecule of the purified MoPrP23-231; they were
also verified by detection of a disulfide-bridged peptide fragment subsequent to trypsin digestion of native rPrP (not shown).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
MALDI-mass spectra of MoPrP23-231 and
determination of a single disulfide bond. A,
S-carbamidomethylation of cysteines in freshly purified
moPrP23-231. A1, MALDI mass spectrum of purified recombinant
mouse PrP 23-231 (MoPrP23-231). A2, mass spectrum
of non-reduced MoPrP23-231 incubated with IAM. MoPrP23-231 (1 mg/ml) in
0.1 M Tris-HCl, pH 8.0, 1 mM EDTA, 6 M guanidine hydrochloride was incubated without DTT at room
temperature for 1 h. The non-reduced MoPrP23-231 was incubated
with 50 mM iodoacetamide (IAM) at room
temperature in the dark for 30 min. A3, mass spectrum of
reduced MoPrP23-231 incubated with IAM. MoPrP23-231 (1 mg/ml) in 0.1 M Tris-HCl, pH 8.0, 1 µM EDTA, 6 M guanidine hydrochloride was incubated with 10 µM DTT at room temperature for 1 h. The reduced
MoPrP23-231 was incubated with 50 mM IAM at room
temperature in the dark for 30 min. B, molecular mass of
fresh or stored MoPrP23-231. Mass spectra of MoPrP23-231 freshly
purified (B1), stored in H2O at 20 °C for 6 months (B2), or stored in H2O for 24 months
(B3).
|
|
Multimeric Forms of Mouse PrP23-231--
Purified MoPrP23-231
migrated as a single band with a molecular mass of 23 kDa upon gel
electrophoresis, irrespective of whether it was loaded with or without
reducing agent (Fig. 2, lanes
1 and 2). Negro et al. (45) reported that
the monomers of reduced and non-reduced recombinant PrP migrated with
the same mobility on SDS gels but that the non-reduced protein could
form multimers, most probably the result of intermolecular disulfide
bond formation. Since a low protein concentration was used here for
oxidative refolding (to avoid formation of interchain S-S bonds), the
absence of multimers in fresh protein preparations was not unexpected (Fig. 2, lanes 1 and 2). However, aged
preparations of MoPrP23-231 examined subsequent to storage (lanes
3 and 4) and/or lyophilization (lanes 5 and
6) behaved differently and in a manner reminiscent of
recombinant chicken PrP (46). For example, fresh MoPrP23-231 (1 mg/ml)
in distilled water was lyophilized, stored at
20 °C for 3 months,
and then analyzed. After resuspension in the same volume of distilled
water, a band corresponding to a putative dimer was detected (Fig. 2,
lanes 5 and 6). With longer periods of storage,
the effect was more pronounced. After lyophilization and storage at
20 °C for 8 months, putative dimers, trimers (~70 kDa),
tetramers (~96 kDa), and yet larger oligomers were observed (Fig. 2,
lanes 7 and 8). This phenomenon was apparent in
independent preparations of MoPrP23-231.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
PrP23-231 monomers and multimers. Twenty
micrograms of freshly purified, stored, and/or lyophilized MoPrP23-231
in distilled water were electrophoresed on 10-20% Tricine-SDS gel, as
indicated, and stained with Coomassie Blue. The molecular weights of
the protein markers are indicated to the left of the figure.
Even-numbered lanes represent samples boiled in the presence
of -mercaptoethanol ( -ME). Positions of
multimers and monomers are shown to the right side of the
figure.
|
|
To extend this finding, protein preparations were imaged by in
situ atomic force microscopy (AFM), a technique whereby a sharp tip is raster-scanned over a surface, providing a true
three-dimensional image of features at molecular scale resolution. In
contrast to traditional imaging techniques, AFM enables examination of
biomolecular structures and processes under near-native conditions
without the need for exhaustive and possibly damaging sample
treatments. By using this approach, freshly prepared MoPrP23-231
revealed well formed, discrete, and comparatively uniform ellipsoid
particles with dimensions of 85 ± 14 Å × 100 ± 17 Å × ~19 Å (Fig. 3A, and estimated using a standard deviation of ~17% in both lateral
dimensions). The ascertainment of lateral dimensions was made after
accounting for the known tip convolution effect wherein the shape of
the scanning tip contributes to an overestimation of the actual lateral dimensions. Our model, based on a nominal tip diameter of ~20 nm (200 Å), accounts for errors in image analyses and the tip convolution
effect (47). Assuming a semi-ellipsoidal shape, a typical protein
density of 1.36 Da/Å3 with a hydration level of ~0.34 g
of H2O/g of protein, and recognizing that the 26-kDa
MoPrP23-231 molecules occupies a volume of ~24,600 Å3,
these aggregates are consistent with hexameric MoPrP23-231 species. Notably, somewhat larger particles, ~100 ± 17 Å × ~200 ± 34 Å × ~19 Å in size, were observed in the samples of
MoPrP23-231 lyophilized and stored for 8 months. These particles
exhibited a propensity to pile up into taller structures (Fig.
3B, white structures, arrowed).

View larger version (151K):
[in this window]
[in a new window]
|
Fig. 3.
Multimeric forms of PrP23-231 detected by
atomic force microscopy. A shows freshly prepared
MoPrP23-231 analyzed in water, whereas aged MoPrP23-231 (stored for 8 months) analyzed in water is shown in B. Image sizes are
1000 × 1000 nm. Sample height is presented on a gray
scale. C and D represent aged MoPrP23-231
(12 months) incubated for 48 h in the presence of Cu(II)
(C) or Zn(II) (D). Increasing sample height is
represented by purple color, with a side perspective used to
visualize the enhanced formation of aggregates in the Cu(II)-treated
sample. Aged protein (stored 12 months) incubated in water also
contained a small number of aggregates, comparable to the
Zn(II)-incubated sample (not shown).
|
|
Cu(II)-induced Conformational Transitions in MoPrP23-231--
A
solution of MoPrP23-231 in 25 mM
N-ethylmorpholine buffer (used to minimize interactions
between the buffer and divalent cations (48)) and 30 mM KCl
(NEMO-KCI buffer) was examined by far-UV CD (Fig.
4). As anticipated (33), this sample
exhibited a CD spectrum indicative of a high
-helical content, with
minimum at 208 and 222 nm and a maximum near 195 nm (Fig. 4A,
trace 1). Addition of excess of Cu(II) failed to produce spectral
changes (Fig. 4A, traces 2 and 3). Although
analysis of MoPrP23-231 stored at
20 °C for 3 months yielded
similar results in the absence of cations (Fig. 4B, trace
1), addition of 2-, 5-, 7-, and 10-fold molar excess of Cu(II)
resulted in a progressive attenuation of the spectral components
indicative of
-helical structure and an increment in components
indicative of
-sheet plus turn (Fig. 4B, traces 2-5). By
using the neural net algorithm of Andrade et al. (42), at
5× molar excess of Cu(II)
-helix was reduced from 32 ± 2.16 (S.D.) to 22.8 ± 1.0% (n = 4 experiments), and
-sheet was increased from 13.75 ± 1.71 to 26.7 ± 1.7%.
Similar data were obtained from a different aged preparation of
MoPrP23-231 (Fig. 4C, traces 2-5); in both cases
spectral changes were apparent within minutes of Cu(II) addition.
Incubation of the same aged batch of MoPrP23-231 with Ni(II) and Zn(II)
failed to produce similar spectral changes (Fig. 4, D and
E, traces 2 and 3). To address the issue of
solubility, aliquots of the Cu-MoPrP23-231 preparations analyzed in
Fig. 4C were removed subsequent to spectroscopic analysis
and pelleted at 100,000 × g for 30 min.
Electrophoretic analysis of the supernatant fraction failed to reveal
any appreciable diminution in protein content, making it unlikely that
CD spectral changes were due to protein precipitation (not shown).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Cu(II)-induced conformation transitions in
MoPrP23-231. CD spectra of 10 µM fresh
(A), stored 3 months (B), or lyophilized and
stored 8 months (C-E) MoPrP23-231 measured in NEMO-KCl
buffer, pH 7.4 (A, trace 1). Effects of increasing
concentrations of Cu(II) (50 and 100 µM) are shown in
A, traces 2 and 3. The effects of
increasing concentrations of Cu(II) (20, 50, 70, and 100 µM) are also shown in B and C,
traces 2-5, respectively. The effects of increasing
concentrations (50 and 100 µM) of Zn2+
(D) and Ni2+ (E) are shown in
traces 2 and 3. The ordinate axis (molar
ellipticity [ ]) was calibrated by using a protein concentration
determined by amino acid hydrolysis.
|
|
Cu(II)-induced Formation of Proteinase K-resistant PrP
Fragments--
In further experiments we investigated another hallmark
of PrPSc, protease resistance, using a preparation of
MoPrP23-231 that exhibited Cu(II)-induced CD spectral changes. Protein
in NEMO-KCl buffer was incubated with or without 7-fold excess
CuCl2 at room temperature for 0, 6, 12, 24, 48 or 96 h
at which time one-half of each sample was digested with PK. Bands of
monomer (23 kDa) and dimer (46 kDa) were observed in starting material
prior to PK treatment (Fig. 5A,
odd-numbered lanes). Samples mixed with copper and digested
directly and those incubated with Cu(II) for a period of 6 h prior
to digestion were completely degraded (Fig. 5A, lanes 6 and
8), indicating that Cu(II) does not interfere with the PK
digestion and is compatible with a previously described sensitivity to
protease digestion (33). Incubation of the MoPrP23-231 with Cu(II) for
12, 24, 48, and 96 h resulted in the appearance of two
PK-resistant species of ~13.3 and 11.6 kDa (Fig. 5B, lanes 10, 12, 14, and 16). To determine specificity, the same
batch of lyophilized protein was resuspended and incubated for 48 h at room temperature with or without 7-fold excess of
CuCl2, ZnCl2, MgCl2,
CaCl2, MnCl2, CuSO4,
NiSO4, or FeSO4 and digested with PK. Only
copper (in the chemical form of either CuCl2 or
CuSO4) induced formation of PK-resistant PrP fragments. The
greater amount of protein concentrations loaded in this experiment
allows a third 9.8-kDa species to be detected in addition to the 13.3- and 11.6-kDa peptide fragments (Fig. 5B, lanes 4 and 14).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 5.
Cu(II)-induced formation of
protease-resistant fragments of MoPrP23-231. A, time
course. An 8 µM solution of MoPrP23-231 (lyophilized,
stored for 8 months) in NEMO-KCl buffer, pH 7.4, was incubated without
any divalent ion at room temperature for 0 (lanes 1 and
2) or 96 h (lanes 3 and 4) or
with 56 µM CuCl2 at room temperature for 0, 6, 12, 24, 48 or 96 h (lanes 5-16). After incubation
with or without Cu2+, one-half of each sample was digested
with PK (the ratio of MoPrP:PK was 15:1 by mass, equivalent to a PK
concentration of 12.5 µg/ml) at 37 °C for 16 h (the
even-numbered lanes). Odd-numbered lanes show
samples without PK digestion. The faint band of apparent mobility,
28-kDa, visible in some digested samples corresponds to PK. The
position of PK-resistant species is designated by a bracket
(and also in B and C). B, effect of
divalent ions. A 16 µM solution of lyophilized
MoPrP23-231 in NEMO-KCI buffer, pH 7.4, was incubated without any
divalent ion (lanes 1 and 2) or with 128 µM CuCl2 (lanes 3 and
4), ZnCl2 (lanes 5 and 6),
MgCl2 (lanes 7 and 8),
CaCl2 (lanes 9 and 10),
MnCl2 (lanes 11 and 12),
CuSO4 (lanes 13 and 14),
NiSO4 (lanes 15 and 16), or
FeSO4 (lanes 17 and 18). After
incubation with or without divalent ions, one-half of each sample was
digested with PK (the ratio of MoPrP:PK was 15:1 by mass, equivalent to
a PK concentration of 25 µg/ml) at 37 °C for 16 h (the
even-numbered lanes). Odd-numbered lanes show
samples without PK digestion. C, effect of protein aging.
Lanes 1, 2, 5, and 6 represent a fresh
preparation, and lanes 3, 4, 7, and 8 represent a
preparation stored at 20 °C for 3 months. Protein was used at a
concentration of 8 µM, with Cu(II) added to a
concentration of 50 µM in the lanes 5-8. PK
was added to a concentration of 12.5 µg/ml and incubated for 16 h at 37 °C as indicated (PrP:PK = 15:1). Proteins were
visualized with Coomassie Blue staining of the 10-20% Tricine-SDS
polyacrylamide gel.
|
|
The effect of protein "age" was also examined. Freshly purified
protein (Fig. 5C, lanes 1, 2, 5, and
6) or protein stored for 3 months at
20 °C (Fig.
5C, lanes 3, 4, 7, and 8) was
incubated alone or with CuCl2 in NEMO-KCl buffer at room
temperature for 48 h. Subsequent to electrophoresis, bands of
monomer (23 kDa) were observed in all samples without PK treatment
(Fig. 5C, lanes 1, 3, 5, and 7). As before,
samples incubated without copper and digested with PK were degraded
(Fig. 5C, lanes 2 and 4). While stored
MoPrP23-231 developed PK-resistant forms of apparent molecular mass of
13.3, 11.6, and 9.8 kDa (Fig. 5C, lane 8); freshly purified MoPrP23-231 incubated with copper was fully digested (Fig. 5C, lane 6).
N-terminal Sequencing of Protease-resistant PrP
Peptides--
Protease-resistant PrP peptides formed in the presence
of Cu(II) were subjected to N-terminal sequencing. The 13.3-kDa species corresponds to two approximately equimolar species, consistent with
peptides commencing at residues 116 and 118 of mouse PrP (44). The
cleavage sites between residues 115
116 and 117
118 are not
identical to those observed when MoPrP23-231 is purified in the absence
of protease inhibitors (cleavage at 116
117, 118
119, and
120
121) (33). A less abundant protein species was also present
within this size-fractionated sample, and the deduced sequence of
T(G)ENFTE aligns with residues 192-199 of mouse PrP (TKGENFTE).
Presumably, as protein samples were not treated with reducing agent
prior to preparative electrophoresis, a subset of the 13.3-kDa peptide
species commencing at residues 116 or 118 are cleaved proximal to
residue 192 but fail to dissociate into two parts because of the
disulfide linkage between residues 178 and 213. Two attempts to obtain
N-terminal sequences from the 11.6-kDa peptide failed to yield a unique
sequence but instead yielded weak signals corresponding to peptides
present in the 13.3- and 9.8-kDa peptides. Finally, the 9.8-kDa peptide
yielded the sequence SKKRPKP (where S indicates
the serine residue inserted to stabilize the protein in E. coli) corresponding the to N terminus of recombinant MoPrP23-231
(33). This N-terminal assignment predicts molecular masses of 9605 and
9733.2 Da, assuming C termini defined by residues 115 and 117, respectively, and thereby demonstrates some similarity to chicken PrP
fragments detected in vivo (49).
Cu(II)-induced Transitions in PrP23-231 Monitored by AFM and
EM--
Effects of Cu(II) upon the structure of aged preparations of
PrP23-231 were also detected by the AFM technique, using Zn(II)-treated samples as controls. It should be noted that AFM signals in Fig. 3,
C and D, are presented as three-dimensional
images to emphasize sample height. The most striking feature of this
analysis was evident in the Cu(II)-treated samples (Fig.
3C), where large and comparatively uniform assemblies of
particles were apparent. Thus, whereas the small particles observed by
AFM retained an ellipsoidal appearance comparable to that of Fig. 3,
A and B, large aggregated structures were also
observed, 500 ± 85 Å wide and extending 120-150 Å off the
surface of the mica. These can be seen as "hillocks" in the false
three-dimensional perspective (lighter-colored signals, Fig.
3C). In the case of Zn(II)-treated aged protein samples
(Fig. 3D), the small (~60 Å tall) particles observed by
in situ AFM appeared more interconnected in the lateral
dimensions than samples prepared in water (not shown) or Cu(II) (Fig.
3C), perhaps forming a network on the underlying mica
surface. In sum these data suggest that Cu(II) produces a further
assembly of MoPrP23-231 complexes (perhaps hexamers, as noted above) to
form yet larger supramolecular aggregates.
Since protein preparations enriched in PrPSc assemble into
structures variously termed "prion rods" or "scrapie-associated
fibrils" (50, 51), electron microscopy was also used to investigate the effects of Cu(II) and other metals on ultrastructure (Fig. 6). The preparation of MoPrP23-231 used
for experiments shown in Figs. 4 and 5 was incubated alone or with
various cations, visualized by negative staining, and observed under
the electron microscope. MoPrP23-231 incubated in the absence of
divalent cations formed amorphous structures that were eradicated by
proteinase digestion (not shown). However, samples incubated in
CuCl2 exhibited rod-like structures with a diameter of
20-30 nm and lengths from 200 to 400 nm (Fig. 6A). In some
instances rod-like structures were assembled together in higher order
aggregates (Fig. 6, B and C). Prion rods show
similarities to the Cu(II)-induced fibrils with a diameter of 25 nm and
lengths <50 to >300 nm (51), although it should be noted prion rod
formation is facilitated by detergent extraction and proteinase K
digestion (45) and dependent upon detergent composition (51). After
incubation of MoPrP23-231 with Cu(II) and PK digestion, aggregates with
a different morphology were observed (Fig. 6,
D-F), perhaps assemblies of small aggregates and with diameters of 30-40 nm and lengths of 50-100 nm. Parallel incubation of PrP23-231 with Ni(II) or Zn(II) failed to produce any
defined morphological structures, either in the absence or presence of
proteinase K (not shown).

View larger version (110K):
[in this window]
[in a new window]
|
Fig. 6.
Negative stain electron microscopy of
Cu(II)-treated MoPrP23-231. A 16 µM solution of
MoPrP23-231 was incubated with 112 µM CuCl2
at room temperature for 4 days. Samples were then digested with PK (the
ratio of protein:PK was 15:1 in microgram) at 37 °C for 16 h
(D-F). A-C show the samples without PK
digestion. The size bar in B representing 100 nm
also applies to A. The size bar for F
represents 200 nm and also applies to C-E.
|
|
No Evidence for Methionine Oxidation in Aged
MoPrP23-231--
Since gel electrophoresis, CD, protease resistance,
AFM, and EM techniques all distinguished between fresh and aged
MoPrP23-231, we attempted to identify a cause for this phenomenon.
Oxidation was a strong candidate as Wong et al. (52) have
reported that oxidative refolding of recombinant mouse PrP results in
selective oxidation of methionine residues. Accordingly, amino acid
hydrolysis was performed on two preparations of "aged" MoPrP23-231
that exhibited both Cu(II)-induced CD spectral changes and the
formation of PK-resistant species. Analyses are presented for Met, His,
Tyr, and Phe (Table I). In no instance
was there a progressive reduction in an amino acid content with respect
to the predicted yield. As there can be systematic errors in the
detection of some amino acid residues subsequent to acid hydrolysis and
high pressure liquid chromatography analysis, we also sought
post-translational alterations by MALDI-TOF mass spectrometry. Fig.
1B1 shows the mass of fresh purified MoPrP23-231 is 23,107 Da (predicted mass of [M + H]+ is 23,107 Da). After
storage in water at
20 °C for 6 or 24 months, the recorded values
are 23,104 or 23,114 Da, respectively (Fig. 1, B2 and
B3). The mass differences between three samples (~10 Da)
are within the instrument mass error (0.05% of the molecular weight at
linear DE mode with the external calibration, corresponding to 11.5 Da
for a protein of this size). These results are compatible with those
obtained by amino acid analysis and do not support the hypothesis of
protein oxidation as a basis for "aging" of MoPrP23-231 (assuming a
predicted mass of 23,123 for MoPrP23-231 oxidized to yield 1 mol of
methionine sulfoxide per protein molecule and based on values of 149.2 Da for methionine and 165.2 Da for methionine sulfoxide).
Deamidation and Aging of MoPrP23-231--
A second possibility for
protein aging is via deamidation. These non-enzymatic covalent
post-translational modifications occur primarily at asparagine
residues, at physiological pH, and through an intramolecular mechanism.
Hydrolysis of deamidated residues generates isoaspartate and aspartate
(in D- and L- forms) in a ratio of
approximately 3:1 (53). Of note, spontaneous deamidation and
isomerization of Asn-108 (equivalent to Asn-107 in MoPrP) has been
reported in a human PrP106-126 peptide. A molecular audit of
MoPrP23-231 revealed the same types of changes at Asn-107, with partial
isomerization of Asp-226 also noted (34). We attempted to verify
deamidation of Asn-107 to yield isoaspartic acid and aspartic acid
using our preparations of aged MoPrP23-231, by exploiting the mass
difference of 1 Da between Asn and Asp/iso-Asp. Since this level of
resolution is not readily attainable by MALDI-MS (Fig. 1), MoPrP23-231
was analyzed subsequent to endoproteolysis. Because of limiting amounts
of aged MoPrP23-231, endoprotease digests were analyzed by MALDI-TOF-MS
without a prior high pressure liquid chromatography purification step.
A tryptic peptide signal with mass at m/z 501.2 Da was found
in all samples analyzed; this corresponds to the protonated peptide YYR
(residues 148-150, predicted mass 502.1) and comprises an internal
control. In contrast, the fragment 106-109 (TNLK) including Asn-107
exhibited a change in mass. In the freshly purified MoPrP23-231, the
TNLK protonated fragment 106-109 had a mass of 475.7 Da (calculated
475.6 Da, Fig. 7, panel 1).
After storage at
20 °C for 6 months, a second signal of 476.7 Da
was observed (Fig. 7, panel 2), likely corresponding to
TDLK, where D refers to both aspartic and isoaspartic acid residues
(which cannot be distinguished by this type of analysis). After storage
for a further 18 months, only the 476.7-Da protonated peptide was
detected (Fig. 7, panel 3).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 7.
Formation of Asp-107 in MoPrP23-231.
Tryptic peptide (residues 106-109 and 148-150) mapping of MoPrP23-231
is shown. MALDI mass spectra of trypsin-digested MoPrP23-231 either
freshly purified (panel 1), stored in H2O at
20 °C for 6 months (panel 2), or stored in
H2O at 20 °C for 24 months (panel 3) are
presented here. Peaks labeled with asterisks are derived
from the matrix.
|
|
Cu(II)-induced Protease-resistant PrP from Brain
Microsomes--
The foregoing experiments indicate that recombinant
MoPrP23-231 characterized by deamidation at residue 107 interacts with Cu(II) to produce molecules with some similarities to
PrPSc. As discussed below, it is plausible that deamidated
forms of PrPC exist in living cells. However, since
PrPSc is formed in vivo from
post-translationally modified PrP (and consequently bears two
N-linked carbohydrate side chains itself), we sought to
examine the effect of Cu(II) on brain-derived PrP by assaying for
protease resistance. Points of particular importance were whether
protease-resistant species were formed and, if so, whether the N
termini lie in the vicinity of codon 90 (like PrP27-30) or in the
vicinity of codons 111 or 117/119/121 (like PrPC and rPrP
breakdown products (33, 54)).
These experiments utilized brain microsome preparations containing
PrPC, with exogenous Cu(II) added to favor stoichiometric
formation of Cu(II)-PrPC complexes. To allow use of the
well characterized 3F4 monoclonal antibody (16, 55), analyses were
performed upon Syrian hamster (SHa) PrPC expressed in
Tg(SHaPrP7) transgenic mice (36) and PrPC from normal human
brain. Microsomal fractions enriched in PrPC in NEMO-KCl
buffer were incubated with or without transition metals at 140 µM for 48 h, at which time one-half of each sample was digested with PK (50 µg/ml at 37 °C for 1 h). Protein
samples were blotted and developed with 3F4 and 6H4 monoclonal
antibodies, which recognize epitopes in the vicinity of residues
108-111 and 142-148, respectively (55, 56). These antibodies detect
~30-kDa PK-resistant forms of PrP when microsomes from
Tg(SHaPrP)7+/
mice (3F4, Fig.
8A; and 6H4, B) or
human brain (Fig. 8C) were incubated for 48 h with
Cu(II); such species were completely absent from controls lacking
exogenous Cu(II) or containing Zn(II) or Ni(II) (Fig. 8, A-C,
lanes 2, 4, and 6). Although attempts were made to use
Fe(III) as an additional negative control, this resulted in the
formation of precipitates. Addition of Sarkosyl to a final concentration of 0.2% prior to digestion, at a concentration equal to
or greater than used by others to detect PrPSc (7), did not
affect the appearance of the PK-resistant species, whereas increasing
detergent to 2% abolished their formation (not shown).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 8.
Cu(II)-induced protease-resistant PrP from
brain microsomes. 40-µl aliquots of microsomal fraction from
Tg7+ mouse brains (A and B) or human
brain (C) were incubated without any divalent ion
(lanes 1 and 2) or with 140 µM
ZnC12 (lanes 3 and 4),
NiSO4 (lanes 5 and 6), or
CuCl2 (lanes 7 and 8) at room
temperature for 48 h. Microsomal preparations presented here were
stored between 2 and 3 months at 20 °C prior to gel analysis.
One-half of each sample was digested with PK (the ratio of protein:PK
was 15:1, equivalent to a PK concentration of 50 µg/ml) at 37 °C
for 1 h (lanes 2, 4, 6, and 8). Samples were
boiled in the Tris glycine-SDS sample loading buffer without
-mercaptoethanol for 5 min then electrophoresed on a 14% SDS
polyacrylamide gel. The proteins were transferred to nitrocellulose
membranes and analyzed by Western blot with anti-hamster/anti-human PrP
monoclonal antibody 3F4 (A and C) or anti-mouse
PrP monoclonal antibody 6H4 (56) (B).
|
|
The size differences between PK-resistant reactions products from
Cu(II)-treated rPrP and microsomal PrP cannot be solely attributed to
carbohydrate moieties because an increment of only ~9 kDa
distinguishes unglycosylated molecules from di-glycosylated PrPc (from
apparent mass of 26 kDa for unglycosylated molecules to up to 35 kDa
(57, 58)), whereas a difference of >16 kDa distinguishes the largest
product deriving from PrP23-231 from the 30-kDa microsomal species.
This indicates that the N terminus of microsomally derived PK-resistant
PrP must lie upstream of residues 116/118, the termini of the 13.3-kDa
fragments from Cu(II)-treated PrP23-231, in agreement with the position
of the 3F4 epitope.
 |
DISCUSSION |
Cu(II)-induced Changes in rPrP and PrPC--
Although
previous studies demonstrate conversion of recombinant PrP to
structures enriched in
-sheet structure (one hallmark of
PrPSc), these experiments involve thermal or chemical
denaturation, acidification, or reduction of the disulfide bond (26,
59, 60). Similarly, chemical denaturants were also featured in early versions of "conversion" reactions seeded by
PrPSc in vitro (61, 62), although they have now
been superceded (63). PrP27-30-like species have also been created by
expression of mammalian PrP in the yeast cytoplasm or under conditions
where disulfide bond formation and N-glycosylation is
attenuated in chemically treated neuroblastoma cells (64, 65). To what
extent some of the more drastic manipulations listed above approximate conditions in living cells is unclear. Our studies demonstrate effects
of Cu(II) on the architecture of prion protein molecules, measured in
terms of aggregation state, secondary structure, and protease
resistance, at neutral pH and in the absence of denaturants and
reducing agents. Zn(II), although also capable of coordination by
histidine residues, failed to induce equivalent transitions in any of
the experiments, with between one and five other transition metals
comprising additional negative controls, depending upon the particular
paradigm. These data confirm the specific interaction between PrP and
Cu(II) (26). Interestingly, Cu(II) has also been shown to affect
multimerization of
-synuclein, a protein implicated in the
pathogenesis of Parkinson's disease (66).
Covalent Changes in Aged MoPrP23-231--
One unanticipated aspect
of our experiments was the profound effect of aging on rPrP
(MoPrP23-231) produced by a standard method of refolding under
oxidative conditions (33, 56, 67). Similar to studies of hamster
PrP29-231 (26), Cu(II) has little effect upon the far-UV CD spectrum of
freshly prepared MoPrP23-231 when analyzed at room temperature.
However, aged preparations exhibit profound changes in the presence of
Cu(II) without recourse to thermal denaturation (26) and acquire, with
kinetics in the order of hours, resistance to proteinase K. Aged
preparations of PrP23-231 also have a propensity to assemble into
multimeric aggregates, detected in denaturing polyacrylamide gels and
by atomic force and electron microscopy. The practical implication of
this finding is that shelf life must be factored as a variable in
studies using rPrP.
Oxidative modification of amino acids containing a sulfur atom or an
aromatic ring was considered as a mechanism for protein aging, as this
may lead to increased exposure of hydrophobic aspects of the protein,
favoring aggregation and protease resistance (68). However, amino acid
analysis of four of the amino acid residues particularly susceptible to
oxidation failed to reveal progressive under-representation with
increasing storage times (Table I). Likewise, analysis by MALDI-MS
failed to reveal an increase in multiples of 16 mass units between
freshly purified MoPrP23-231 and protein stored for 6 or 24 months
(Fig. 1B). Deamidation of Asn to form aspartic or
isoaspartic acid residues, a reaction that proceeds by an
intramolecular reaction at neutral pH and can alter the structural
integrity and biological activity of proteins, was considered as
another possibility (69-71). Sandmeier et al. (34) recently
reported that Asn-108 in the human PrP peptide 106-126 and the
equivalent residue in MoPrP23-231 (Asn-107) undergoes spontaneous
deamidation to produce aspartic or isoaspartic acid residues. This is
compatible with our knowledge of PrP, since while rates of deamidation
can be impeded by secondary structural elements (72), Asn-107 lies
within a region with no assigned structure (40, 41). We used MALDI-MS
to confirm the presence of Asp-107 in our preparations of MoPrP23-231
by analyzing the tryptic peptide 106-109, TNLK. The TNLK signal was
accompanied by a TDLK peptide 1 mass unit heavier (Fig. 7) in material
stored for 6 months, and in material stored for 24 months the
progenitor TNLK peptide was no longer detectable. In addition to the
presence of TDLK peptide paralleling progressive alterations in the
properties of stored mouse PrP (documented in Figs. 2-6), chemical
changes produced by deamidation and isomerization appear plausible on structural grounds as a basis for changes in the properties of MoPrP23-231. First, Asn-107 is highly conserved, being present in the
PRNP gene of chickens and in nearly all mammalian species (73),
including humans and sheep, that are susceptible to natural prion
diseases. It lies in the center of a "conformationally plastic" region that undergoes extensive remodeling in PrPSc and may
include an alternative transmembrane domain (74, 75). Second,
deamidation by virtue of the creation of aspartic acid and/or
isoaspartic acid is predicted to generate a change in charge and a side
chain capable (at least in other proteins) of coordinating Cu(II). It
will be of interest to test the hypothesis that deamidation-related covalent changes compromise the crucial difference between fresh and
aged rPrP, using site-directed mutagenesis in the vicinity of
Asn-107.
Asparagine Modification, Cu(II), and Prion Protein
Biology--
The synergism between Cu(II) and aged, deamidated
PrP prompts a number of questions. What are the precedents for Asn
modification in vivo? Are there indications that
PrPC is modified in this way, and if so, how might
modifications be involved in the physiology and pathobiology of prion
proteins? In fact, there is evidence for deamidation and isoaspartate
formation in vivo in proteins such as hemoglobin and
crystallin (76, 77) and in the paired helical filaments of Alzheimer's
disease, which are comprised of the microtubule-associated protein tau
(78). Strikingly, recent findings on G-coupled proteins indicate that conversion of Asn to Asp may be required to generate abundant forms of
these enzymes and modulate biological activity (79, 80). With regard to
PrPC, it is interesting to note that deamidation is a
spontaneous intramolecular reaction that proceeds at neutral pH. For
PrP23-231, the half-life for conversion of Asn-107 to isoaspartic acid
is about 30 days (34). Assuming a typical lifetime of 5 h for a PrPC molecule (2) and no competing editing processes (since
the repair enzyme protein L-isoaspartylmethyltransferase is
only known in cytosolic and endoplasmic reticulum-retained incarnations
(81, 82)), a small fraction of PrPC molecules might be
predicted to be modified spontaneously at Asn-107 and perhaps at other
sites. Since there are suggestions of mammalian deamidases expressed in
the brain it is also possible that deamidated PrPC might
arise via an enzymatic route (80).
It has been argued that deamidation and racemization of asparagine
residues do not comprise a crucial or obligatory determinant in
formation of PrPSc in rapid models of experimental scrapie
disease, as stoichiometric elevations of altered aspartyl residues are
absent from corresponding PrPSc preparations (35). Thus,
most likely, our findings do not address the fundamental mechanism of
prion replication as it occurs in experimental prion disease. However,
we believe our data may speak to two other issues in the realm of prion
pathobiology. The first issue is that of sporadic prion disease. We
strongly suggest that abnormal PrP species arising by an interaction
between deamidated forms of PrPC and Cu(II) may engender or
serve as precursors to the prions that underlie sporadic prion disease.
The second issue is a potential relationship between deamidation and
prion strains.
The residue C-terminal to Asn is a potent determinant of deamidation
rates in vitro and in vivo (53, 83-85).
Remarkably, in the case of Asn-107, this is the site of a missense
polymorphism (Leu-108
Phe-108) that may control susceptibility to
prion strains (18, 21). Thus comparative studies of deamidation rates
in Leu-108 and Phe-108 variants of PrPC would seem
warranted. Furthermore, as Asn deamidation can generate six covalent
variants in addition to the "parental" L-Asn residue (86)) and 5-8 prion strains can be identified in a given inbred host
(16, 87), could these phenomena be related? In short, could covalent
variants of the PrP backbone comprise strain determinants? Although it
is established that PrPSc from rapidly replicating prion
strains such as 263K and Sc237 includes L-Asn-107 (35, 88),
more slowly replicating strains might encompass covalent derivatives of
Asn-107 generated by rate-limiting deamidative pathways. Although these
notions are currently speculative, our findings suggest that
experiments to catalogue Asn derivatives in brain PrP and to create
mutations at or in the vicinity of codon 107 may provide new insights
into prion disease pathogenesis.
 |
ACKNOWLEDGEMENTS |
We thank Peter Mastrangelo and Maria Gasset
for helpful discussions and Lynle Go and Bob Strome for technical
assistance. We also thank R. Glockshuber, S. Hornemann, and M. Cereghetti for gifts of recombinant MoPrP23-231 and discussions of
unpublished results; R. Rubenstein for 3F4 antibody, and the
Biotechnology Service Center, Department of Clinical Biochemistry,
University of Toronto for peptide sequencing.
 |
FOOTNOTES |
*
This work was supported in part by the Medical Research
Council of Canada, Natural Sciences and Engineering Research Council of
Canada, the Ontario Research and Development Challenge Fund, the
University of Toronto Connaught Fund, Health Canada, the Ontario Mental
Health Foundation, and the Alzheimer Society of Ontario.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b
Supported by a fellowship from the Canadian Red Cross Society.
j
To whom correspondence should be addressed: University of
Toronto, Centre for Research in Neurodegenerative Diseases, Tanz Neuroscience Bldg., 6 Queen's Park Crescent West, Toronto, Ontario M5S
3H2, Canada. Tel.: 416-978-1556; Fax: 416-978-1878; E-mail: david.westaway@utoronto.ca.
 |
ABBREVIATIONS |
The abbreviations used are:
CJD, Creutzfeldt-Jakob disease;
sCJD, sporadic CJD;
PK, proteinase K;
DTT, dithiothreitol;
MOPS, 4-morpholinepropanesulfonic acid;
MALDI-TOF-MS, matrix-assisted laser desorption/ionization time-of flight mass
spectrometry;
IAM, iodoacetamide;
GST, glutathione
S-transferase;
AFM, atomic force microscopy;
Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
 |
REFERENCES |
| 1.
|
Prusiner, S. B.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13363-13383[Abstract/Free Full Text]
|
| 2.
|
Borchelt, D. R.,
Scott, M.,
Taraboulos, A.,
Stahl, N.,
and Prusiner, S. B.
(1990)
J. Cell Biol.
110,
743-752[Abstract/Free Full Text]
|
| 3.
|
Caughey, B.,
and Raymond, G. J.
(1991)
J. Biol. Chem.
266,
18217-18223[Abstract/Free Full Text]
|
| 4.
|
Gasset, M.,
Baldwin, M. A.,
Fletterick, R. J.,
and Prusiner, S. B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1-5[Abstract/Free Full Text]
|
| 5.
|
Pan, K.-M.,
Baldwin, M.,
Nguyen, J.,
Gasset, M.,
Serban, A.,
Groth, D.,
Mehlhorn, I.,
Huang, Z.,
Fletterick, R. J.,
Cohen, F. E.,
and Prusiner, S. B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10962-10966[Abstract/Free Full Text]
|
| 6.
|
McKinley, M. P.,
Bolton, D. C.,
and Prusiner, S. B.
(1983)
Cell
35,
57-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Oesch, B.,
Westaway, D.,
Wälchli, M.,
McKinley, M. P.,
Kent, S. B. H.,
Aebersold, R.,
Barry, R. A.,
Tempst, P.,
Teplow, D. B.,
Hood, L. E.,
Prusiner, S. B.,
and Weissmann, C.
(1985)
Cell
40,
735-746[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Westaway, D.,
Carlson, G. A.,
and Prusiner, S. B.
(1989)
Trends Neurosci.
12,
221-227[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Gibbs, C. J., Jr.,
Gajdusek, D. C.,
and Amyx, H.
(1979)
in
Slow Transmissible Diseases of the Nervous System
(Prusiner, S. B.
, and Hadlow, W. J., eds), Vol. 2
, pp. 87-110, Academic Press, New York
|
| 10.
|
Parchi, P.,
Giese, A.,
Capellari, S.,
Brown, P.,
Schulz-Schaeffer, W.,
Windl, O.,
Zerr, I.,
Budka, H.,
Kopp, N.,
Piccardo, P.,
Poser, S.,
Rojiani, A.,
Streichemberger, N.,
Julien, J.,
Vital, C.,
Ghetti, B.,
Gambetti, P.,
and Kretzschmar, H.
(1999)
Ann. Neurol.
46,
224-233[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Bruce, M. E.
(1993)
Br. Med. Bull.
49,
822-838[Abstract/Free Full Text]
|
| 12.
|
Kimberlin, R. H.,
Walker, C. A.,
and Fraser, H.
(1989)
J. Gen. Virol.
70,
2017-2025[Abstract/Free Full Text]
|
| 13.
|
Kellings, K.,
Prusiner, S. B.,
and Riesner, D.
(1994)
Philos. Trans. R. Soc. Lond-Biol. Sci.
343,
425-430[Medline]
[Order article via Infotrieve]
|
| 14.
|
Bessen, R. A.,
and Marsh, R. F.
(1994)
J. Virol.
68,
7859-7868[Abstract/Free Full Text]
|
| 15.
|
Telling, G. C.,
Parchi, P.,
DeArmond, S. J.,
Cortelli, P.,
Montagna, P.,
Gabizon, R.,
Mastriani, J.,
Lugaresi, E.,
Gambetti, P.,
and Prusiner, S. B.
(1996)
Science
274,
2079-2082[Abstract/Free Full Text]
|
| 16.
|
Safar, J.,
Wille, H.,
Itri, V.,
Groth, D.,
Serban, H.,
Torchia, M.,
Cohen, F. E.,
and Prusiner, S. B.
(1998)
Nat. Med.
4,
1157-1165[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Kanyo, Z. F.,
Pan, K. M.,
Williamson, R. A.,
Burton, D. R.,
Prusiner, S. B.,
Fletterick, R. J.,
and Cohen, F. E.
(1999)
J. Mol. Biol.
293,
855-863[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Westaway, D.,
Goodman, P. A.,
Mirenda, C. A.,
McKinley, M. P.,
Carlson, G. A.,
and Prusiner, S. B.
(1987)
Cell
51,
651-662[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hunter, N.,
Hope, J.,
McConnell, I.,
and Dickinson, A. G.
(1987)
J. Gen. Virol.
68,
2711-2716[Abstract/Free Full Text]
|
|